J&J's Imbruvica tops Arzerra in phase III trial PMLiVE ... is already approved as a second-line therapy for CLL - making sales of £56m in the first nine months of 2013 - although growth has been fairly slow because the product has struggled to displace Roche's Rituxan/MabThera (rituximab) in these patients. |
